@ryannipp.bsky.social
DM for the link or to be added to our mailing list.
@realbowtiedoc.bsky.social
@crisbergerot.bsky.social
@ericroeland.bsky.social
@fionnualacrowley.bsky.social
#pallonc
@ryannipp.bsky.social
DM for the link or to be added to our mailing list.
@realbowtiedoc.bsky.social
@crisbergerot.bsky.social
@ericroeland.bsky.social
@fionnualacrowley.bsky.social
#pallonc
@ascocancer.bsky.social
Early #pallonc became #SoC after Temel 2010 study but billing #Medicare rose from 1.44% to 10.36% (2010-2019)
Greater #supponc advocacy is needed!
🔗:https://ascopubs.org/doi/10.1200/JCO-24-01935
@oncoalert.bsky.social
@ascocancer.bsky.social
Early #pallonc became #SoC after Temel 2010 study but billing #Medicare rose from 1.44% to 10.36% (2010-2019)
Greater #supponc advocacy is needed!
🔗:https://ascopubs.org/doi/10.1200/JCO-24-01935
@oncoalert.bsky.social
[email protected]@hpna-info.bsky.social-NICSO guideline on opioid conversion in adults with cancer?
Read the full guideline or download a set of summary tools on our website: mascc.org/resources/ma...
#SuppOnc #PallOnc @oncoalert.bsky.social
[email protected]@hpna-info.bsky.social-NICSO guideline on opioid conversion in adults with cancer?
Read the full guideline or download a set of summary tools on our website: mascc.org/resources/ma...
#SuppOnc #PallOnc @oncoalert.bsky.social
ascopubs.org/doi/10.1200/...
@ascocancer.bsky.social
#Survivorship #PallOnc #CancerCare
@dcrinews.bsky.social @dukemedschool.bsky.social @dukecancer.bsky.social
ascopubs.org/doi/10.1200/...
@ascocancer.bsky.social
#Survivorship #PallOnc #CancerCare
@dcrinews.bsky.social @dukemedschool.bsky.social @dukecancer.bsky.social
Honored to be a part of this outstanding effort!
Lead by dear colleagues @crisbergerot.bsky.social and @billyrosaphd.bsky.social
#pallonc access in #LMICs 🌎 is limited; @ascocancer.bsky.social guideline varies due to 🔑 systemic barriers.
🔗: ascopubs.org/doi/pdfdirec...
Honored to be a part of this outstanding effort!
Lead by dear colleagues @crisbergerot.bsky.social and @billyrosaphd.bsky.social
#pallonc access in #LMICs 🌎 is limited; @ascocancer.bsky.social guideline varies due to 🔑 systemic barriers.
🔗: ascopubs.org/doi/pdfdirec...
@fumikochino.bsky.social
@tingtingzhang.bsky.social
@ericroeland.bsky.social
@darcyburbage.bsky.social
@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
If you’re joining us online, tell us what your favorite at-home virtual conference snack is below!
@fumikochino.bsky.social
@tingtingzhang.bsky.social
@ericroeland.bsky.social
@darcyburbage.bsky.social
@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
Please note that submissions which include a Conference Scholarship application are due by December 17, 2025.
All other abstracts are due by January 16, 2026.
Learn more: mascc.org/annualmeetin...
@oncoalert.bsky.social #SuppOnc #PallOnc
Please note that submissions which include a Conference Scholarship application are due by December 17, 2025.
All other abstracts are due by January 16, 2026.
Learn more: mascc.org/annualmeetin...
@oncoalert.bsky.social #SuppOnc #PallOnc
Let me know who I should be following and who loves to engage.
pallonc supponc GIonc
Let me know who I should be following and who loves to engage.
pallonc supponc GIonc
Today I was organizing some papers and found these 3 #rejection letters from medical school from Stanford, Yale, and UCSF.
Normalizing rejection is just as important as sharing your wins. #ShareyourRejection
These are the questions my husband @granaghan.bsky.social asks me. And I have no answers.
#hapc #pallonc #medsky #meded 😳
These are the questions my husband @granaghan.bsky.social asks me. And I have no answers.
#hapc #pallonc #medsky #meded 😳
@crisbergerot.bsky.social
@pallonccop.bsky.social
@fionnualacrowley.bsky.social
@mazietsangmd.bsky.social
@ascocancer.bsky.social
@darcyburbage.bsky.social
@rsedhom.bsky.social
@crisbergerot.bsky.social
@pallonccop.bsky.social
@fionnualacrowley.bsky.social
@mazietsangmd.bsky.social
@ascocancer.bsky.social
@darcyburbage.bsky.social
@rsedhom.bsky.social
link.springer.com/article/10.1...
@cancercaremascc.bsky.social
#PallOnc #PalliativeCare #CancerResearch
link.springer.com/article/10.1...
@cancercaremascc.bsky.social
#PallOnc #PalliativeCare #CancerResearch
See you soon! #pallonc #supponc
@crisbergerot.bsky.social
@realbowtiedoc.bsky.social
See you soon! #pallonc #supponc
@crisbergerot.bsky.social
@realbowtiedoc.bsky.social
www.sciencedirect.com/science/arti...
#CancerCare #CancerResearch #PallOnc
www.sciencedirect.com/science/arti...
#CancerCare #CancerResearch #PallOnc
Today on #WorldCancerDay, I continue in my quest to unite cancer care and support. We have a long way yet to go:
✨ ⬆️ Quality
✨ ⬇️ Cost 💰
✨ Equitable access
✨ ⬆️ #SurvOnc
@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
Today on #WorldCancerDay, I continue in my quest to unite cancer care and support. We have a long way yet to go:
✨ ⬆️ Quality
✨ ⬇️ Cost 💰
✨ Equitable access
✨ ⬆️ #SurvOnc
@oncoalert.bsky.social
@weoncologists.bsky.social
@pallonccop.bsky.social
#supponc #pallonc #ASCO #HRQL #PatientCentered #cancer #research
oncodaily.com/blog/155066
#supponc #pallonc #ASCO #HRQL #PatientCentered #cancer #research
oncodaily.com/blog/155066
@realbowtiedoc.bsky.social
@crisbergerot.bsky.social
@tingtingzhang.bsky.social
@fionnualacrowley.bsky.social
@realbowtiedoc.bsky.social
@crisbergerot.bsky.social
@tingtingzhang.bsky.social
@fionnualacrowley.bsky.social
jnccn.org/view/journal...
#PallOnc #Immunotherapy #SuppOnc
jnccn.org/view/journal...
#PallOnc #Immunotherapy #SuppOnc